ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

Methylphenidate Extended-Release
ADHD
Sleep-wake disorders
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

Methylphenidate Extended-Release CII

Generic Name and Formulations:
Methylphenidate HCl 10mg, 20mg; ext-rel tabs.

Company:
Various generic manufacturers

Therapeutic Use:

Indications for Methylphenidate Extended-Release:

Attention deficit hyperactivity disorder.

Adults and Children:

Swallow whole. May use methylphenidate extended-release tabs in place of methylphenidate tabs when the 8-hr dose of methylphenidate extended-release corresponds to the titrated 8-hr dose of methylphenidate. Max 60mg daily.

Contraindications:

During or within 14 days of MAOIs. Marked anxiety, tension, agitation. Glaucoma. Motor tics. Tourette's syndrome in patient or family.

Warnings/Precautions:

History of drug dependence or alcoholism; monitor for abnormal behavior. Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder; screen for risk before initiation. Consider discontinuing if new psychotic/manic symptoms occur. Monitor for new or worsening aggressive behavior or hostility. Seizure disorder. Peripheral vasculopathy, including Raynaud's Phenomenon; monitor for digital changes. Monitor growth (esp. children), BP, HR, CBCs, differential, platelet counts. Reduce dose or discontinue if paradoxical aggravation of symptoms occur. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.

Interactions:

See Contraindications. Caution with pressor agents, anticonvulsants. May increase levels of anticonvulsants, oral anticoagulants, tricyclics, phenylbutazone. Antagonizes guanethidine, other antihypertensives. Risk of serotonin syndrome with serotonergic drugs.

See Also:

METHYLIN CHEWABLE

METHYLIN ORAL SOLUTION

Methylphenidate

Pharmacological Class:

CNS stimulant.

Adverse Reactions:

Insomnia, nervousness, CNS overstimulation, anorexia, weight loss, abdominal pain, nausea, dizziness, headache; priapism, hypertension, tachycardia, visual disturbances.

How Supplied:

Tabs, ext-rel tabs—contact supplier; Chew tabs—100; Oral soln—500mL

Indications for Methylphenidate Extended-Release:

Narcolepsy.

Adults and Children:

Swallow whole. May use methylphenidate extended-release tabs in place of methylphenidate tabs when the 8-hr dose of methylphenidate extended-release corresponds to the titrated 8-hr dose of methylphenidate. Max 60mg daily.

Contraindications:

During or within 14 days of MAOIs. Marked anxiety, tension, agitation. Glaucoma. Motor tics. Tourette's syndrome in patient or family.

Warnings/Precautions:

History of drug dependence or alcoholism; monitor for abnormal behavior. Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder; screen for risk before initiation. Consider discontinuing if new psychotic/manic symptoms occur. Monitor for new or worsening aggressive behavior or hostility. Seizure disorder. Peripheral vasculopathy, including Raynaud's Phenomenon; monitor for digital changes. Monitor growth (esp. children), BP, HR, CBCs, differential, platelet counts. Reduce dose or discontinue if paradoxical aggravation of symptoms occur. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.

Interactions:

See Contraindications. Caution with pressor agents, anticonvulsants. May increase levels of anticonvulsants, oral anticoagulants, tricyclics, phenylbutazone. Antagonizes guanethidine, other antihypertensives. Risk of serotonin syndrome with serotonergic drugs.

See Also:

METHYLIN CHEWABLE

METHYLIN ORAL SOLUTION

Methylphenidate

Pharmacological Class:

CNS stimulant.

Adverse Reactions:

Insomnia, nervousness, CNS overstimulation, anorexia, weight loss, abdominal pain, nausea, dizziness, headache; priapism, hypertension, tachycardia, visual disturbances.

How Supplied:

Tabs, ext-rel tabs—contact supplier; Chew tabs—100; Oral soln—500mL

Sign Up for Free e-newsletters